Here's more news. Looks like LGND is getting ready to make and sell PRODUCTS!
Philip A. Duffy Named Vice President, Technical Operations at
Ligand Pharmaceuticals Inc.
Thursday, February 19, 1998 05:56 PM
>
SAN DIEGO, Feb. 19 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) has announced
the appointment of Philip A. Duffy to the newly created position of Vice President, Technical
Operations. Mr. Duffy will oversee Ligand's chemical, formulations and analytical development
activities for commercial products, as well as manufacturing, purchasing, and materials management
functions.
Prior to joining Ligand, Mr. Duffy served as Vice President, Product Supply for Schein Bayer
Pharmaceutical Services, Inc., a position he held since 1994. From 1993 to 1994, he was the principal
of Philip A. Duffy & Associates, a New Jersey-based pharmaceutical consulting practice. From 1992 to
1993, he was Corporate Vice President, Materials Management at ICN Pharmaceuticals Inc. Mr. Duffy
has held management positions with a number of pharmaceutical companies during the past 20 years,
including careers with Schering-Plough Inc., G.D. Searle & Co., and Baxter International.
Mr. Duffy earned a bachelor of arts degree in Economics from Marquette University and an MBA in
Management and Organization Behavior at George Williams College. He served in the U.S. Army
from 1966 until 1969, and completed Officer Candidate School for the U.S. Army Transportation Corps
in 1967. In recognition of his service, Mr. Duffy was awarded the Bronze Star with Oak Leaf Cluster, the
Army Commendation Medal with "Valor" and Vietnam Service Ribbons.
Ligand Pharmaceuticals Incorporated, founded in 1987, is a leader in gene transcription technology,
particularly intracellular receptors (IR) technology and Signal Transducers and Activators of
Transcription (STATs). Ligand has applied IR and STATs technology to the discovery and
development of small molecule drugs to enhance therapeutic and safety profiles and to address
major unmet patient needs in cancer, women's and men's health and skin diseases, as well as
osteoporosis, metabolic, cardiovascular and inflammatory disease.
This press release may contain certain forward looking statements by Ligand and actual results could
differ materially from those described as a result of factors, including, but not limited to, the following.
There can be no assurance that any product will be successfully developed, that regulatory approvals
will be granted, that patient and physician acceptance of these products will be achieved or that final
results of human clinical trials will be consistent with any interim results, or that results will be supportive
of regulatory approvals required to market products. Ligand undertakes no obligation to update the
statements contained in this press release after the date hereof.
SOURCE Ligand Pharmaceuticals Inc.
CONTACT: Susan E. Atkins, Vice President, Corporate Communications & Investor Relations of
Ligand Pharmaceuticals, 619-550-7687 |
